a public good project by the
Synthesis
Company
of California

© 2026

Jean Bergeron | doi.page

0 works0 citations0 h-index

Jean Bergeron

Publications by Year

Research Areas

Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy, Cancer, Lipids, and Metabolism

Most-Cited Works

→ Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events(2015)2,268 cited
→ Hypertriglyceridemic Waist(2000)931 cited
→ Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial(2012)577 cited
→ Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial(2015)462 cited
→ Race, Visceral Adipose Tissue, Plasma Lipids, and Lipoprotein Lipase Activity in Men and Women(2000)388 cited
→ Effects of Endurance Exercise Training on Plasma HDL Cholesterol Levels Depend on Levels of Triglycerides(2001)332 cited

→ Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women.(1999)

192 cited

→ Apolipoprotein A-I Conformation in Reconstituted Discoidal Lipoproteins Varying in Phospholipid and Cholesterol Content(1995)188 cited

→ Blood lipid response to 20 weeks of supervised exercise in a large biracial population: The HERITAGE family study(2000)173 cited

→ A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I(2016)122 cited